Patients with breast cancer brain metastases historically have a poor prognosis. In this single-institution cohort study of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases, we found no improvement in survival after brain recurrence over time despite wide adoption of HER2etargeted therapies. This highlights the importance of continued development of novel brain penetrant therapies for patients with HER2epositive metastatic disease to extend survival and improve quality of life. Background: Given the wide adoption of human epidermal growth factor receptor 2 (HER2)-targeted therapies for advanced HER2epositive breast cancer, we studied the natural history of patients with HER2epositive breast cancer brain metastases (BCBM) over time. Patients and Methods: Patients with HER2epositive BCBM identified from a prospectively maintained database at the University of North Carolina were divided into 3 cohorts by year of BCBM diagnosis. Cohorts were selected by year of HER2etargeted therapy US Food and Drug Administration approval. Overall survival (OS), time to first metastasis, time to BCBM, and BCBM survival were estimated by the Kaplan-Meier method. Associations between OS after BCBM and clinical variables were assessed by Cox proportional hazards regression models. Results: One hundred twenty-three patients were identified. Median age was 51 years, and 58% were white and 31% African American. OS from initial breast cancer diagnosis improved over time: 3.6 years (95% confidence interval [CI], 2.8-6.1) in the 1998-2007 cohort, 6.6 years (95% CI, 4.5-8.6) in the 2008-2012 cohort, and 7.6 years (95% CI, 4.4-9.6) in the 2013-2015 cohort (P ¼ .05). While time from initial diagnosis to first metastasis did not differ (P ¼ .12), time to BCBM increased over time (2.6 years [95% CI, 1.3-3.5] for 1998-2007; 2.6 years [95% CI, 2.1-4.3] for 2008-2012, and 3.3 years [95% CI, 2.2-6] for 2013-2015; P ¼ .05). Although OS from BCBM did not significantly differ by cohort, patients who received HER2etargeted therapy after BCBM had a prolonged OS (2.1 years [95% CI, 1.6-2.6] vs. 0.65 years [95% CI, 0.4-1.3]; P ¼ .001). Conclusion: OS from initial breast cancer diagnosis significantly improved over time for patients with HER2epositive breast cancer who develop BCBM, now exceeding 7 years; survival from BCBM diagnosis may now exceed 2 years.
Introduction
One-third of women with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer will be diagnosed with brain metastases (BCBM) during their disease course. 1 HER2epositive breast cancer carried a poor prognosis in the preetargeted therapy era. 2, 3 Even after the approval of trastuzumab in the metastatic setting, overall survival (OS) from diagnosis of BCBM was less than 1.2 years. 1, 4 Over the past 2 decades, treatment of patients with advanced
HER2epositive breast cancer has evolved significantly as a result of the approval of several HER2etargeted therapies now incorporated into routine practice, which have markedly improved the prognosis of metastatic HER2epositive breast cancer. What is not yet clear is whether improved HER2edirected therapies have had the same impact among patients with BCBM. Variability in the chemical characteristics of the newer HER2etargeted therapies, and thus differing abilities to penetrate the bloodebrain barrier (BBB) to either prevent BCBM or control existing metastatic lesions, suggest that these agents may have a positive impact on the recurrence rates in the brain and survival of patients with HER2epositive BCBM. Multiple trials evaluating HER2edirected agents beyond trastuzumab have reported on brain outcomes. Although lapatinib with capecitabine has been shown to delay time to brain progression compared to trastuzumab in patients with metastatic HER2epositive disease, there was no difference in incidence of BCBM between the 2 groups. 5 Among patients with disease that progressed while receiving trastuzumab, lapatinib plus capecitabine compared to capecitabine alone is associated with a reduced risk of brain as the site of first progression. 6 In patients with radiation-naive HER2epositive BCBM, lapatinib plus capecitabine resulted in a reduction in BCBM volume from baseline in 84% of patients, suggesting it may be a reasonable first-line treatment. 7 Moving beyond lapatinib, an exploratory analysis of patients from the CLEOPATRA trial reported that in those with HER2epositive metastatic breast cancer treated with trastuzumab and docetaxel, while the addition of pertuzumab did not change the incidence of the brain as the first site of disease recurrence, it did delay the onset of and trend toward an increased OS after diagnosis of BCBM. 8 While ado-trastuzumab emtansine (TDM-1) was initially thought to have limitations to crossing the BBB similar to trastuzumab, several reports illustrate intracranial responses in the setting of HER2epositive BCBM. [9] [10] [11] [12] The EMILIA study comparing TDM-1 with lapatinib plus capecitabine in patients with advanced HER2epositive disease pretreated with trastuzumab found that while the proportion of patients with brain progression was the same in both groups, in patients with preexisting BCBM, TDM-1 conferred a prolonged OS. 10 The TH3RESA study found that in patients with advanced HER2epositive breast cancer pretreated with 2 or more HER2etargeted agents, those in the TDM-1 group, including those with previously treated BCBM, had a longer progression-free survival than the physician's-choice group.
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These emerging data indicate that patients with HER2epositive metastatic disease are benefiting from therapeutic advances. In light of these advances, however, a collective analysis of BCBM outcomes in the modern era has yet to be performed. Thus, we performed a single-institution cohort study to examine the magnitude of this benefit in patients with BCBM during the era of modern HER2etargeting.
Methods
Patients included in this study had metastatic HER2epositive breast cancer with BCBM at any point during their disease course. Informed consent was not obtained from participants included in the study because a waiver of consent and waiver of Health Insurance Portability and Accountability Act authorization were both approved by the University of North Carolina (UNC) Biomedical institutional review board on May 9, 2015.
Relevant data for this population were retrieved using 2 clinical databases at UNC. The UNC Breast Cancer Metastatic Database contains demographic, clinical, and treatment data on all metastatic breast cancer patients treated at the UNCeChapel Hill Cancer Hospital from 2012 to the present. A second database collected information on breast cancer patients treated at UNC between 1991 and 2012. Within the databases, HER2 positivity was defined as either positive by immunohistochemistry or amplified by fluorescence in-situ hybridization. Tumors were hormone receptor positive if estrogen receptor, progesterone receptor, or both were positive, and hormone receptor negative if both estrogen receptor and progesterone receptor were negative.
A total of 123 patients were identified from both databases, yielding the cohort for this study. Patient follow-up data were available through May 2015, with a median follow-up of 1.75 years (range, 0.1-12 years) from BCBM diagnosis. UNC institutional review board approval was obtained to conduct this retrospective analysis. Of note, UNC has a dedicated BCBM clinic and research program, initiated on August 1, 2012.
Statistical Analysis
Patients were divided into 3 cohorts for analysis as defined by year of BCBM diagnosis. Cohort time intervals were selected on the basis of year of HER2etargeted therapy US Food and Drug Administration (FDA) approval: 1998-2007 for trastuzumab, 2008-2012 for lapatinib, and 2013-2015 for pertuzumab and TDM-1. The Kaplan-Meier method and log-rank test were used to estimate and compare OS from initial breast cancer diagnosis, time from initial breast cancer diagnosis to first metastatic diagnosis, time from initial breast cancer diagnosis to BCBM, time from first metastatic diagnosis to BCBM, and OS from BCBM diagnosis. Subsequent pairwise log-rank tests were performed if the overall test was significant. Univariable and multivariable Cox proportional hazards regression modeling was used to evaluate associations of clinical variables with OS from BCBM. All analyses were conducted by SAS 9.4 statistical software (SAS Institute, Cary, NC).
Results

Demographics and Treatment Pattern of Patient Population
Demographic and clinical characteristics for patients in each cohort are listed in Table 1 Table 2 lists the treatment received for BCBM. Of these therapies, radiotherapy was the first therapeutic intervention after BCBM diagnosis in most patients across all time cohorts (79% 1998-2007, (Figure 1 ).
Time to First Metastatic Diagnosis and Time to Brain Recurrence
Median time from initial breast cancer diagnosis to first metastatic diagnosis was 1.52 years (95% CI, 1.07-2.03), median time from first metastatic diagnosis to BCBM was 1.11 years (95% CI, 0.76-1.38), and median time from initial breast cancer diagnosis to BCBM was 2.88 years (95% CI, 2.22-3.42). Time from initial breast cancer diagnosis to first metastatic diagnosis numerically increased over time but was not statistically significant (P ¼ .12) (Figure 2 ). Time from first metastatic diagnosis to BCBM diagnosis also did not significantly change over time (P ¼ .13) (Figure 3 ). 
Brain MetastasiseSpecific Survival
OS from BCBM diagnosis was 1.51 years (95% CI, 1.24-2.05) for the entire cohort and was not significantly different over time (P ¼ .24) ( Figure 5 ). Interestingly, those who received HER2etargeted therapy (62%) after BCBM diagnosis had a median OS of 2.11 years (95% CI, 1.55-2.60) compared to 0.65 years (95% CI, 0.38-1.25) in those who did not receive HER-2etargeted treatment (P ¼ .001) (Figure 6 ).
Demographic and clinical characteristics of patients who received
HER2etargeted therapy for BCBM compared to those who did not are listed in Table 3 . A higher proportion of white subjects received HER2etargeted therapies compared to African American subjects (69% vs. 45%, P ¼ .03). A higher proportion of patients in earlier cohorts received HER2etargeted therapies after BCBM than in the recent cohort (62% for 1998-2007, 76% for 2008-2012, and 46% for 2013-2015, P ¼ .02).
Univariable and Multivariable Cox Regression Analysis
Univariable analysis shows that receipt of HER2etargeted therapy after BCBM diagnosis was the only demographic, clinical, and treatment variable significantly associated with OS from BCBM diagnosis (hazard ratio 0.51, 95% CI 0.33-0.78) ( Table 4 ). Given this result, the finding that receipt of HER2etargeted therapy differs by both race and cohort, and sample size limitations, a multivariable model was fit to investigate if this relationship held after controlling for race and year of BCBM diagnosis. Receipt of HER2etargeted therapy after BCBM diagnosis remained significantly associated with longer OS from BCBM diagnosis ( Table 5 ).
Discussion
The purpose of this analysis was to reexamine the natural history of HER2epositive metastatic breast cancer with brain progression in the era of newer HER2etargeted therapies. Among a cohort of 123 patients with HER2epositive BCBM treated at UNCeChapel Hill, there has been no significant change in survival after a diagnosis of BCBM over time. However, the median time to diagnosis of BCBM from initial breast cancer diagnosis appears to have increased by 9 months in the most recent era, 2013-2015, during which patients with HER2epositive disease have the benefit of multiple targeted agents. We attribute this increased time to BCBM diagnosis to both a prolonged time from initial breast cancer diagnosis to first metastatic diagnosis and from first metastatic diagnosis to BCBM diagnosis. Collectively, this leads to a delayed diagnosis of BCBM over time. These data provide a new historical control and framework for the manner in which we design novel clinical trials for this patient population, both in the prevention and activetherapy settings.
The advent of new HER2etargeted therapies contributes to a longer time from initial breast cancer diagnosis to BCBM diagnosis. [9] [10] [11] [12] We demonstrated that patients exposed to any HER2etargeted treatment after their diagnosis of BCBM experienced a significantly longer OS than those not so exposed. Fewer patients in the 2013-2015 cohort received HER2etargeted therapy after BCBM compared to the 2 earlier cohorts. Because our survival analyses show that we are extending the time from initial diagnosis to BCBM diagnosis, we assert that in recent years, patients are diagnosed with BCBM later with more aggressive systemic disease and thus do not have the opportunity to benefit from HER2etargeted therapies. Another contributor is that many have already received newer HER2etargeted therapies before intracranial recurrence, as seen in this analysis, with over half of patients diagnosed with BCBM between 2013 and 2015 receiving pertuzumab and 12% receiving TDM-1 for nonebrain metastatic disease. Furthermore, over 80% of patients received HER2etargeted therapy for nonebrain metastatic disease, which was not significant across time cohorts. Thus, once brain metastases occurred, the majority of available antieHER2etargeted therapies had already been prescribed.
A greater proportion of white subjects in our cohort received HER2etargeted therapy compared to African American subjects after BCBM diagnosis. This aligns with previous studies demonstrating racial disparity in HER2etargeted therapy throughout the disease course. 13, 14 Notably, multivariable modeling did not indicate race to be significantly related to mortality after BCBM Figure 6 Overall Survival After Breast Cancer Brain Metastasis Diagnosis by Receipt of HER2eTargeted Therapy diagnosis, with receipt of HER2etargeted therapy being the only significant variable. This aligns with a previous study indicating no race-specific differences in survival after BCBM diagnosis. 4 Despite the approval of 3 new HER2etargeted therapies during the course of this study, there is room for improvement in the survival of patients after a diagnosis of HER2epositive BCBM. This underscores the potential importance of new brain-penetrant therapies: COX2-MMP1/CCL7 has been identified as a targetable pathway for BCBM. 15 TPI-287, a novel brain permeable taxane, is in phase 2 clinical trials (NCT01332630). 16, 17 Several clinical trials evaluating novel brain-permeable agents are ongoing: 4-demethyl-4-cholesteryloxycarbonylpenclome chemotherapy (NCT02038218) 18 ; eribulin mesylate, a microtubule inhibitor (NCT02581839) 19 ; cabozantinib, a tyrosine kinase and VEGFR2 inhibitor (NCT02260531) 20 ; and abemaciclib, a cdk4/6 inhibitor (NCT02308020). 21 Efficacy of ANG1005, a novel formulation of paclitaxel bound to angio-pep that binds the low-density lipoprotein receptorerelated protein 1 receptor on the BBB, is being investigated for recurrent brain metastases (NCT02048059). 22 Two small-molecule HER2etargeted agents are being evaluated: neratinib, an irreversible inhibitor of erbB1, HER2, and erbB4 (NCT01494662); and KD019, a tyrosine kinase inhibitor of HER2, EGFR, and VEGFR2/KDR (NCT02154529). [23] [24] [25] A phase 2 randomized trial of neratinib with paclitaxel versus trastuzumab with paclitaxel showed no difference in progression-free survival, but the combination with neratinib may delay the onset and reduce the frequency of central nervous system progression. 24 Other clinical trials are evaluating combinations of brain-permeable FDA-approved therapies: lapatinib, everolimus, and capecitabine (NCT01783756) 26 ; everolimus with trastuzumab and vinorelbine (NCT01305941) 27 ; and lapatinib with cabazitaxel, a brain-permeable taxane (NCT01934894). 28 We remain hopeful that these strategies will translate into improvements in the survival of patients after a diagnosis of HER2epositive BCBM. While the number of brain metastases at initial BCBM diagnosis significantly increased over time, this did not influence survival after BCBM recurrence. We attribute this increased number of brain lesions at BCBM diagnosis to improvements in magnetic resonance imaging detection and resolution of smaller lesions that may not have been detected on older imaging platforms.
Our multivariable model shows receipt of HER2etargeted therapy after BCBM was significantly associated with prolonged OS after BCBM, even after controlling for race and time cohort. These results differ from a previous model, the BreasteGraded Prognostic Assessment of Sperduto et al, 29 intended to identify prognostic factors associated with survival in patients with BCBM, due to our focus on HER2epositive disease and the development of this prior model before wide utilization of novel HER2etargeted therapies. We hypothesize that as the therapeutic landscape of HER2epositive breast cancer evolves, and as more data are uncovered regarding the biology of brain metastases, tools such as the BreasteGraded Prognostic Assessment will likely expand and become more precise. We recognize several limitations in our analysis. First, the UNCeChapel Hill Cancer Hospital is a referral center with a dedicated BCBM clinic, which may attract patients with systemically different diseases. Second, a small number of patients received pertuzumab and TDM-1 due to their relatively recent FDA approval in 2012 and 2013, respectively. Thirty-one patients (25%) were still alive at the time of data extraction, and thus over time we expect that a higher proportion of patients will be exposed to these newer therapies as results from ongoing trials comparing efficacy of existing HER2etargeted agents become available. Third, we do not have data on the presence of extracranial disease at BCBM diagnosis for the cohorts before 2012. In the univariate analysis, presence of extracranial disease at BCBM diagnosis was not significant over time, which is likely explained by the paucity of data. Finally, the retrospective nature of this analysis does not allow causation to be drawn between the natural history of the disease and the specific therapy received. In summary, OS of patients with HER2epositive BCBM has increased, largely as a result of prolonged time between initial breast cancer diagnosis and diagnosis of BCBM over the decades. The lack of improvement in survival once BCBM are diagnosed support the continued development of novel brain-penetrant therapies for patients with HER2epositive metastatic disease to extend survival and improve quality of life.
Clinical Practice Points
One-third of women with metastatic HER2epositive breast cancer will be diagnosed with BCBM during their disease course. After approval of trastuzumab in the metastatic setting, OS from diagnosis of BCBM was less than 1.2 years. The effect of FDA approval of additional HER2etargeted agents including lapatinib, pertuzumab, and TDM-1 on the natural history of disease in these patients is less clear. In this cohort of patients with HER2epositive BCBM, while the OS from initial breast cancer diagnosis has increased over time, survival after diagnosis of brain recurrence has not improved. However, patients who were exposed to any HER2etargeted agent after BCBM diagnosis had a longer survival after BCBM diagnosis than those not so exposed. These data provide a new historical control and framework for the manner in which we design novel clinical trials for this patient population, both in the prevention and active-therapy settings. These data should encourage clinicians to utilize the available HER2etargeted agents when clinically indicated in patients with HER2epositive brain metastases.
